Genelux (NASDAQ:GNLX – Get Free Report) and Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.
Institutional & Insider Ownership
37.3% of Genelux shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Genelux and Foghorn Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genelux | $10,000.00 | 11,581.44 | -$32.15 million | ($0.86) | -2.98 |
| Foghorn Therapeutics | $30.91 million | 3.84 | -$74.28 million | ($0.98) | -2.04 |
Genelux has higher earnings, but lower revenue than Foghorn Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Genelux has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500.
Profitability
This table compares Genelux and Foghorn Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genelux | N/A | -205.85% | -138.79% |
| Foghorn Therapeutics | -175.78% | N/A | -31.17% |
Analyst Ratings
This is a breakdown of recent ratings for Genelux and Foghorn Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genelux | 1 | 0 | 3 | 1 | 2.80 |
| Foghorn Therapeutics | 1 | 5 | 4 | 0 | 2.30 |
Genelux presently has a consensus price target of $18.00, suggesting a potential upside of 603.12%. Foghorn Therapeutics has a consensus price target of $6.67, suggesting a potential upside of 233.33%. Given Genelux’s stronger consensus rating and higher probable upside, equities analysts plainly believe Genelux is more favorable than Foghorn Therapeutics.
Summary
Foghorn Therapeutics beats Genelux on 8 of the 15 factors compared between the two stocks.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
About Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
